Global Markets for Allergy Diagnostics and Treatments is expected to reach $52.7 billion by 2021
NEW YORK, June 26, 2017 /PRNewswire/ -- Highlights
· The global allergy diagnostic and treatment market reached nearly $35.3 billion in 2015. This market is expected to increase from nearly $40.0 billion in 2016 to $52.7 billion in 2021 at a compound annual growth rate (CAGR) of 5.9% for 2016-2021.
· Treatments market is expected to grow from $33.4 billion in 2016 to $44.4 billion in 2021 at a CAGR of 5.9% from 2016 through 2021.
· Diagnostics market is expected to grow from $5.0 billion in 2016 to nearly $6.9 billion in 2021 at a CAGR of 6.6% from 2016 through 2021.
· This report is designed to provide a comprehensive look at the global allergy diagnostic, immunotherapy and treatment markets.
· The report provides a brief explanation of different allergic disorders with global incidence rates, discusses the different types of allergy diagnostic tests and their applicability in diagnosing various allergens, describes classes of allergy treatment products and provides an overview of the growing immunotherapy market.
· A section on diagnostic products such as skin prick and patch tests, provocation testing, and antibody allergen testing.
· Specific chapters that focus on testing and treatment in three distinct geographical areas: Americas, EMRA and Asia.
· Providing information to intelligently evaluate market trends in the diagnostic, immunotherapy and allergy treatment markets.
- The global allergy diagnostic and treatment market reached nearly $35.3 billion in 2015. This market is expected to increase from nearly $40.0 billion in 2016 to $52.7 billion in 2021 at a compound annual growth rate (CAGR) of 5.9% for 2016-2021.
- Treatments market is expected to grow from $33.4 billion in 2016 to $44.4 billion in 2021 at a CAGR of 5.9% from 2016 through 2021.
- Diagnostics market is expected to grow from $5.0 billion in 2016 to nearly $6.9 billion in 2021 at a CAGR of 6.6% from 2016 through 2021.
Introduction
This report is designed to provide a comprehensive look at the global allergy diagnostic, immunotherapy and treatment markets.
The report provides a brief explanation of different allergic disorders with global incidence rates, discusses the different types of allergy diagnostic tests and their applicability in diagnosing various allergens, describes classes of allergy treatment products and provides an overview of the growing immunotherapy market.
The report organizes information from diverse sources into a cohesive unit that includes:
- A section on diagnostic products such as skin prick and patch tests, provocation testing, and antibody allergen testing.
- An overview section on allergies and five categories of prescription allergy products including: antihistamines and combinations; sympathomimetics, decongestants and combinations; corticosteroids; mast cell stabilizers; and leukotriene receptors.
- Specific chapters that focus on testing and treatment in three distinct geographical areas: Americas, EMRA and Asia.
- A company profiles section that provides background information on companies active in the diagnostic and treatment arenas.
Prescription and over-the-counter medications are further broken down into specific types of administration. Each subsegment is covered in depth with regard to: oral, spray, topical and ocular applications; current treatments, market size and market participants; potential research and development; and forecasted market size and growth.
Study Goals and Objectives
The objective of this study is to present an in-depth look at the diagnostic, immunotherapy and allergy treatment markets by:
- Providing information to intelligently evaluate market trends in the diagnostic, immunotherapy and allergy treatment markets.
- Identifying and discussing market segments and providing rationale for their growth.
- Tracking significant advances within the market and analyzing their impact on the future of the market.
Reasons for Doing This Study
According to the World Allergy Organization (WAO), between 30% and 40% of the world's population is affected by one or more allergic conditions. Complex allergies that involve polysensitization and multiple organ involvement are increasing in number, leading to potentially higher morbidity and greater demands on health care systems.
This BCC Research study is presented as a valuable basic market reference and summary of activity in the global diagnostic, immunotherapy and allergy treatment markets.
The study will:
- Provide an overview of the global allergy diagnosis and treatment market.
- Analyze the current industry and its major players.
- Explore new therapeutics and diagnostics and their impact on future market development.
- Address market development by product type.
- Provide regional market analysis for diagnostics, immunotherapy and treatments.
Senior and marketing personnel, corporate and product planners, investment analysts, investors, and venture capitalists can use this report to analyze the changing environment and keep abreast of current and potential opportunities within the global allergy diagnostic, immunotherapy, and allergy treatment markets.
Scope of Report
This BCC Research report is designed to provide a comprehensive look at the global allergy diagnostic, immunotherapy, and treatment markets. The geographic areas covered by the report include the Americas region (i.e., Canada, U.S., Mexico, and Central and South America); the EMRA region (i.e., Europe, the Middle East, Russia, and Africa); and the Asian region (i.e., Japan, China, India, Australia, New Zealand, and other Asian Pacific countries).
The report provides a brief explanation of different allergic disorders with global incidence rates; discusses the different types of allergy diagnostic tests and their applicability in diagnosing various allergens; describes classes of allergy treatment products; and provides an overview of the growing immunotherapy market.
The report organizes information from diverse sources into a cohesive unit that includes:
- A section on diagnostic products such as skin prick and patch tests, provocation testing, and antibody allergen testing.
- An overview section on allergies and five categories of prescription allergy products including antihistamines and combinations; sympathomimetics, decongestants and combinations; corticosteroids; mast cell stabilizers; and leukotriene receptors.
- Specific chapters that focus on testing and treatment in three distinct geographical areas: Americas, EMRA and Asia.
- A company profiles section that provides background information on companies active in the diagnostic and treatment arenas.
Information Sources
The primary data collection methodology for this report focused on information provided by industry personnel through Web-based sources or interviews; government agencies; industry observers; and industry professional organizations.
In addition to these primary data sources, secondary data research techniques included a literature search of medical, government, and business sources. Sources include, but are not limited to, Quest Diagnostics' Health Trends 2011; the Mayo Clinic; the Generic Pharmaceutical Association; the World Allergy Organization (WAO); the American Academy of Allergy, Asthma and Immunology (AAAAI); the Asthma and Allergy Foundation of America; Allergy, Asthma & Clinical Immunology; the Journal of Asthma; Proceedings of the National Academy of Sciences; and Bioanalysis.
Methodology
The collected data were analyzed to determine specific findings and forecasts. Once these forecasts were obtained, they were validated with primary sources. It should be pointed out thatthat, while many factors were considered in constructing different models, the projections are ultimately speculative.
As a composite of the opinions and assessments of interviewees, the author, other analysts and secondary sources, these projections represent something of a consensus. However, all recognize that the relative importance of selected factors could change at any time with new technologies and new products, and thus change the direction of the market projections.
Geographic Breakdown
The geographic areas covered by the report include the Americas region (i.e., Canada, U.S., Mexico and Central and South America), the EMRA region (i.e., Europe, the Middle East, Russia and Africa) and the Asian region (i.e., Japan, China, India, Australia, New Zealand and other Asia-Pacific countries).
Summary and Highlights
The current global allergy diagnostic and therapeutic market was worth nearly $39.6 billion in 2016 and is expected to grow at a compound annual growth rate (CAGR) of 5.9% to nearly $52.7 billion by 2021. The allergy diagnostic and therapeutic market is lucrative and has potential to grow due to growth in allergies globally, higher healthcare expenditure and increase in pollution and urbanization.
According to the World Allergy Organization (WAO), between 30% and 40% of the world's population is affected by one or more allergic conditions. In the U.S., the Centers for Disease Control and Prevention estimates that more than 50 million individuals are affected by allergic diseases. A disproportionate number of individuals affected by allergies are young children and teenagers under 18 years of age, increasing the burden of allergic diseases as they become adults.
Allergic conditions are the most common health issues that U.S. children face and affect 40% of children. Additionally, studies have found strong links between allergies and asthma. Complex allergies that involve polysensitization and multiple organ involvement are increasing, leading to potentially higher morbidity and greater demands on healthcare systems.
Allergy Types
Allergies are usually grouped by the type of trigger associated with them, the time of year during which they occur or where symptoms appear on the body. Current groupings include environmental (time of year, indoor and outdoor), food, latex, insect, skin and eye. Additionally, unpredictable allergies (with potentially severe reactions) to drugs and biological agents are becoming problematic.
A contributing factor to increasing allergic reactions seems to be climate change. Climate changes affect pollen counts, the presence or absence of stinging insects and the presence or absence of molds associated with allergic diseases.
Projected Global Market
Global Allergy Diagnostic Market
The global diagnostic market is growing at a CAGR of 6.6%, driven by several macro trends such as a globally aging population, environmental changes, lifestyle changes, improving healthcare infrastructure and expenditure, changes in food habits and growth of urban populations. Because there are no current cures for allergies, the burgeoning market for immunotherapy may offer some hope for a cure for some allergen sensitivities.
The immunotherapy market is expected to grow at a CAGR of 3.9% and perhaps gain momentum as therapies currently prescribed in Europe and Asia gain a foothold in the U.S. Reasons for the growth of the immunotherapy market include demand for sublingual vaccines, continuous ongoing clinical trials and extensive drug pipeline.
Allergy testing can be done through a skin prick, subcutaneous or patch analysis, provocation testing or blood analysis. The standard diagnostic tool is the skin test, but industry representatives believe there is a substantial and growing market for blood analysis testing, particularly in the U.S. and developing markets. The in vitro test segment is expected to grow in the next few years due to higher demand for less invasive diagnostic methods, accurate results and growing laboratory automation.
Global Immunotherapy Market
According to a 2011, WAO paper, sublingual immunotherapy (SLIT) is widely accepted and used in European, South American, and Asian countries, including Australia. In April 2014, the U.S. Food and Drug Administration (FDA) approved three sublingual allergen extract products for the treatment of five- grass (i.e., Timothy, Orchard, Perennial Rye, Kentucky Blue Grass and Sweet Vernal) pollen allergies for individuals 10 years through 65 years of age.
The medications include Oralair, developed by Stallergenes, and Ragwitek for ragweed pollen, and Grastek from Merck. This expanded market will drive the immunotherapy market at a CAGR of 3.9%.
On March 1, 2017, the FDA approved Merck's Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite-induced nasal inflammation (allergic rhinitis [AR]), with or without eye inflammation (conjunctivitis), in people 18 years through 65 years of age.
Global Allergy Medication Market
The global allergy medication market is driven by: an increasing number of individuals with allergies; intense competition, particularly from generic formulations; continuing urbanization in developing countries; increasing awareness; extensive drug pipeline; and expanding pharmaceutical markets in BRIC (i.e., Brazil, Russia, India and China) countries.
There are five types of allergy medications currently available: antihistamine and antihistamine combinations; sympathomimetics, decongestants and combinations; corticosteroids; mast cell stabilizers; and leukotriene receptors. Antihistamines and corticosteroids lead the prescription, generic and over-the-counter (OTC) medication markets.
Regional Diagnostic, Immunotherapy and Treatment Market Leaders
Diagnostic Market
The Americas market, lead by the U.S., constitutes approximately 52% of the allergy diagnostic market, followed by Europe and Asia with 35% and 13%, respectively. Market growth will be led by the Asian region, with strong diagnostic allergy markets in Australia and Japan. The European market is led by sales in Germany, followed by France and Italy.
Immunotherapy Market
The Americas market is expected to expand, driven primarily by an increase in the number of allergy patients and a high awareness level relating to allergy therapeutics and FDA approval, as well as the introduction of SLIT products to the market.
The EMRA (Europe, Middle East, Russia and Africa) market is considered a mature market, with Eastern European countries driving the growth. The Asian market is projected to expand based on macroeconomic factors such as increasing urbanization in the region, an aging population, the exploitation of an underserved Japanese market and continued development of the Australian market, as well as the growth needs and improving healthcare infrastructure in China.
Treatment Market
Many allergy products have lost patent protection during 2010 through 2017 and will continue to lose protection through 2020. Hence, the generics market is expected to continue to grow, while the prescription market is projected to remain in the low single-digit percentage growth range. The generic allergy medicine market is projected to contribute nearly 40% of the global revenues by 2020.
Antihistamines dominate the allergy therapeutics market due to usage benefits and wide applications.
The following table projects the global allergy diagnostic and treatment market by type through 2021. Diagnostic products include skin prick, patch and intradermal products, as well as antibody testing products. Immunotherapy products include subcutaneous and sublingual products. Treatments include prescription, generic and OTC drugs. Data for 2015 are provided for historical purposes.
Read the full report: http://www.reportlinker.com/p02720121/Global-Markets-for-Allergy-Diagnostics-and-Treatments.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article